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ABSTRACT
Introduction Diabetic kidney disease (DKD) is the 
leading cause of end- stage kidney disease worldwide 
and a major cause of premature mortality in diabetes 
mellitus (DM). While improvements in care have reduced 
the incidence of kidney disease among those with DM, 
the increasing prevalence of DM means that the number 
of patients worldwide with DKD is increasing. Improved 
understanding of the biology of DKD and identification of 
novel therapeutic targets may lead to new treatments. A 
major challenge to progress has been the heterogeneity of 
the DKD phenotype and renal progression. To investigate 
the heterogeneity of DKD we have set up The East and 
North London Diabetes Cohort (HEROIC) Study, a secondary 
care- based, multiethnic observational study of patients 
with biopsy- proven DKD. Our primary objective is to 
identify histological features of DKD associated with kidney 
endpoints in a cohort of patients diagnosed with type 1 
and type 2 DM, proteinuria and kidney impairment.
Methods and analysis HEROIC is a longitudinal 
observational study that aims to recruit 500 patients 
with DKD at high- risk of renal and cardiovascular events. 
Demographic, clinical and laboratory data will be collected 
and assessed annually for 5 years. Renal biopsy tissue will 
be collected and archived at recruitment. Blood and urine 
samples will be collected at baseline and during annual 
follow- up visits. Measured glomerular filtration rate (GFR), 
echocardiography, retinal optical coherence tomography 
angiography and kidney and cardiac MRI will be performed 
at baseline and twice more during follow- up. The study 
is 90% powered to detect an association between key 
histological and imaging parameters and a composite 
of death, renal replacement therapy or a 30% decline in 
estimated GFR.
Ethics and dissemination Ethical approval has been 
obtained from the Bloomsbury Research Ethics Committee 
(REC 18- LO-1921). Any patient identifiable data will be 
stored on a password- protected National Health Services 
N3 network with full audit trail. Anonymised imaging data 
will be stored in a ISO27001- certificated data warehouse.
Results will be reported through peer- reviewed 
manuscripts and conferences and disseminated to 
participants, patients and the public using web- based and 
social media engagement tools as well as through public 
events.
INTRODUCTION
Diabetes mellitus (DM) and associated 
complications are among the biggest global 
health challenges of the 21st century. In 
developed countries, owing to advances in 
early diagnosis and prevention, there have 
been improvements in DM management and 
a decline in the incidence of DM complica-
tions. However, this progress is overshad-
owed by the ever- rising absolute numbers of 
people with DM and the rapidly expanding 
Strengths and limitations of this study
 ► This is the first longitudinal diabetic kidney disease
(DKD) study involving a multiethnic cohort of patients 
that aims to deepen our understanding of the patho-
physiological differences and disease phenotypes in
patient populations with a high prevalence of diabe-
tes and at moderate/high risk of renal progression.
 ► Standardised inclusion criteria, patient mix and bi-
opsy proven diagnosis will differentiate The East and 
North London Diabetes Cohort (HEROIC) from pre-
vious DKD studies and will provide insight into the
marked clinical heterogeneity of DKD.
 ► The longitudinal study design coupled with serial
collection of clinical data, biological samples and
novel imaging parameters will provide a unique
platform for future scientific investigation.
 ► Non- invasive quantitative MRI techniques may pro-
vide readily accessible markers of diagnosis, prog-
nosis and treatment effect in patients with DKD.
 ► The size of study may limit our ability to detect
ethnicity- specific associations between risk factors
and outcomes.
2 Mccafferty K, et al. BMJ Open 2020;10:e033923. doi:10.1136/bmjopen-2019-033923
Open access 
prevalence of DM in low- income and middle- income 
countries.1
Due to the associated chronic metabolic abnormalities, 
many patients with DM develop complications as a conse-
quence of microvascular and macrovascular dysfunction,2 
including DKD. Consequently, DKD is a common compli-
cation of DM, with approximately 20% of patients with 
type 2 DM in England and Wales meeting criteria for 
chronic kidney disease (CKD) when estimated using data 
from primary care.3 DKD is the leading cause of end- stage 
kidney disease (ESKD) both in the UK4 and throughout 
the world.5 With 42% of all patients with ESKD in the 
USA having a diagnosis of DKD.6
Although the extent of albuminuria is recognised to 
be a strong predictor of adverse renal and cardiovascular 
outcomes, clinically, DKD is heterogeneous with respect 
to presentation, histopathology and rate of progression.7 
Previous efforts to better understand this variability have 
been complicated by the inclusion of patients with both 
CKD and diabetes in studies without histopathological 
confirmation of disease, despite recognition that up to 
40% of kidney biopsies still show histological features of 
isolated diabetic glomerulosclerosis despite the presence 
of atypical clinical features of non- DKD.8 Moreover, the 
proposed pathogenic mechanisms that underlie DKD 
are multifactorial, complex and may include direct meta-
bolic injury (such as hyperglycaemia and dyslipidaemia), 
microvascular ischaemia, epigenetic reprogramming, 
disordered cellular repair and inflammation.9 10 To date, 
the majority of published DKD cohort studies have been 
conducted in homogenous (usually white European) 
populations, despite clear recognition that ethnicity has 
an important impact on the prevalence of diabetes and 
severity of kidney disease.11 12 Describing the molecular 
pathology of kidney dysfunction in ethnically diverse 
patient groups may facilitate the identification of specific 
subtypes of DKD, thereby allowing targeted surveillance 
and treatment.
East and North Central London is one of the most 
ethnically diverse and socially deprived areas of Europe 
with a high prevalence of DM and associated compli-
cations (figure 1).13 The ethnicity of East and North 
London is distinct from the general population of 
the UK: the boroughs of London (Camden, Hackney, 
Islington, Newham, Tower Hamlets, Barnet and 
Enfield), where HEROIC is primarily recruiting from, 
have a significantly smaller population of white British 
people (35% vs 80%) but a much larger population 
of Asian, Black, mixed race and other (online supple-
mentary table 1). Through longitudinal assessment of 
a multiethnic patient cohort with biopsy confirmed 
DKD and at high risk of developing adverse kidney 
and cardiovascular outcomes (as demonstrated by esti-
mated glomerular filtration rate (eGFR) trajectory and/
or levels of proteinuria), The East and North London 
Diabetes Cohort (HEROIC) aims to describe the natural 
history of kidney dysfunction and development of asso-
ciated complications.
Aside from serum markers that allow estimates of 
kidney function, useful insight into the degree of under-
lying kidney damage can only be gained by invasive 
tissue sampling. However, innovative MRI techniques 
have shown promise in the non- invasive quantification 
of scarring, as well as providing functional measures of 
perfusion.14 Use of serial MRI will allow detailed charac-
terisation of the structural and functional renal15 16 as well 
as cardiac and vascular17 changes that occur in parallel 
with progression of DKD (including left ventricular 
hypertrophy (LVH), myocardial fibrosis and measures of 
arterial stiffness). Indeed, cardiovascular parameters are 
of specific interest because, based on other cohort study 
data, more patients in the HEROIC cohort will die from 
cardiovascular causes than will reach ESKD.18 Similarly, 
detailed assessment of retinal microvasculature by optical 
coherence tomography angiography (OCT- A)19 will 
provide a non- invasive, longitudinal window on microvas-
cular changes that occur in DKD.
OCT- A is a non- invasive technique for imaging the 
microvasculature of the retina and choroid that uses 
laser light reflectance of the surface of moving red blood 
cells to accurately depict the microvasculature through 
different segmented areas of the eye, thus eliminating 
the need for intravascular dyes. The procedure is brief, 
and there are no major associated risks. Swept- source 
OCT- A (SS- OCT- A) allows different vascular layers, from 
the superficial and deep retina as well as the choriocapil-
laris to be individually segmented and analysed.20 OCT- A 
offers advantages over fluorescein angiography and 
colour fundus photography as it can detect diabetic reti-
nopthy earlier in the disease, it allows more reliable diag-
nosis and grading of diabetic retinopathy and its response 
to treatment and with quantitative measurement of the 
microvascualr changes in the retina may provide insight 
into the pathophysiology of retinopathy.21
Figure 1 White/non- white population (Asian, black, 
mixed race and other) of London (left) and deaths due to 
diabetes (SMR; right, based on 2833 male deaths due 
to diabetes based on data from the office for national 
statistics). Camden (C); City and Hackney (H); Enfield (E); 
Haringey (R); Islington (I); Newham (N) and Tower Hamlets 
(T). Images reproduced from: http://www.theguardian.com/
graphic/0,5812,1395103,00.html and https://www.ucl.ac.uk/
ineqcities/atlas/cities/london/disease-specific-mortality/
diabetes-mellitus. SMR, standardised mortality ratio.
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This offers a further advantage over fluorescein angiog-
raphy and colour fundus photography.
Finally, establishment of a biobank linking clinical data, 
biosamples and imaging markers will permit assessment 
of novel predictors and mediators of disease progression, 
as well as providing a resource for establishing biolog-
ical validity using a panel of established urine and blood 
injury markers. Patients will also consent to future linking 
of their data to national routine health records to allow 
capture of long- term follow- up data. The primary and 
subsidiary aims of HEROIC are outlined in table 1.
In summary, HEROIC is a secondary care- based, multi-
ethnic observational study of patients with biopsy- proven 
DKD. The primary objective is to identify histological 
features of DKD associated with kidney endpoints in a 
cohort of patients diagnosed with type 1 and type 2 DM, 
proteinuria and kidney impairment.
METHODS AND ANALYSIS
Study population and inclusion criteria
HEROIC is a prospective multicentre observational cohort 
study that will recruit patients with type 1 and type 2 DM 
primarily from within the seven boroughs of East and 
North Central London. Patients with moderate or high 
risk of progression of DKD (see figure 2) will be invited 
to take part. After screening, confirmation of DKD will be 
obtained by kidney biopsy and thereafter participants will 
be followed annually for up to 5 years. figure 2 illustrates 
a flow diagram of the referral, screening and enrolment 
processes. online supplementary table 2 details the full 
study inclusion and exclusion criteria.
HEROIC recruitment is planned over 24 months or 
until 500 subjects have been entered into the study. In 
addition to patients with DKD, HEROIC will also recruit 
up to 10 healthy individuals without DKD who will 
undergo MRI at each site in order to optimise the renal 
and cardiac MRI protocol before study participants with 
DKD are imaged. The imaging sequences are not used 
in standard clinical practise for imaging the kidney and 
therefore optimisation is necessary. table 2 details the 
schedule of visits and assessments.
Table 1 Primary and secondary objectives of HEROIC
Objective
Primary objective To identify histological features of confirmed DKD associated with endpoints in a cohort of patients 
diagnosed with type 1 and type 2 DM, proteinuria and renal impairment.
Secondary objectives 1. To describe the radiological progression of structural and functional MRI renal parameters in DKD 
and associate these parameters with disease progression and severity.
2. To describe the progression of structural and functional cardiac MRI imaging features in DKD and the
association of these parameters with disease progression.
3. To describe the progression of arterial stiffness in DN and the association of these MRI parameters
with disease progression.
4. To investigate the association between MRI- based and histological estimates of kidney fibrosis.
5. To describe the prevalence of non- diabetic kidney disease in patients preferred to secondary care,
but otherwise represent an unselected multiethnic patient cohort with diabetes, and either heavy
proteinuria or rapidly declining kidney function in East and North London.
6. To describe the retinal microvascular phenotype and associate these with DKD progression using
OCT- A at baseline and at years 1 and 5 of the study.
7. To generate a biobank of clinical specimens and linked database that will enable additional
explorative studies to be undertaken that seek to further identify mechanistic insights and biomarkers
associated with DKD progression.
DKD, diabetic kidney disease; DM, diabetes mellitus; DN, diabetic nephropathy; HEROIC, The East and North London Diabetes Cohort; 
OCT- A, optical coherence tomography angiography.
Figure 2 Flow chart of study design that consists of referral, 
screening and consent of patients with moderate or high risk 
of renal progression (defined as those with heavy proteinuria 
uACR >30 mg/mmol, and/or a ≥5 mL/year decline in eGFR 
calculated across at least three measurements across ≥6 
months prior to study enrolment). Screening and enrolment of 
patients with moderate or high- risk DKD confirmed on renal 
biopsy. Participants will be followed up annually for up to 5 
years. ACR, albumin to creatinine ratio; CKD, chronic kidney 
disease; DKD, diabetic kidney disease; eGFR, estimated 
glomerular filtration rate; HEROIC, The East and North 
London Diabetes Cohort; uACR, urinary ACR.
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Informed consent and study governance
Informed consent will be sought from all participants 
prior to study entry. Subjects will consent to undertake 
investigations as set out in the schedule of activities and for 
long- term access to primary and secondary care follow- up 
data including blood test results. HEROIC is overseen by 
a study executive committee that delegates the day- to- day 
running of the project to an operational steering group.
Study procedures
Study visits will correspond to routine clinic appoint-
ments at baseline and will then occur annually for up to 5 
years. Study procedures are outlined in table 2.
Biopsy visit
Patients will undergo a kidney biopsy at the start of the 
study. The risks and benefits of undergoing a kidney 
biopsy, including a biopsy being conducted for research 
purposes, will be discussed with each individual. Patients 
will attend their local study centre for a kidney biopsy 
as per standard clinical practice with follow- up in 1 of 2 
medical centres.
The biopsy will be reported and scored according to 
an established pathological classification of DKD.22 This 
classification leads to a score on up to five dimensions 
(glomerular, interstital inflammation, fibrosis, small and 
large vessels) each scored between 0 and either 2, 3 or 
4. Given the range of inclusion criteria, we would expect
a range of diabtetes- induced glomerular, interstitial
and vascular pathology to be evident. If there are other
features seen on the biopsy that suggest an additional
non- diabetic kidney disease phenotype requiring active
intervention (eg, membranous nephropathy or renal
Table 2 Schedule of visits and assessments
Screening Biopsy Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6*†
Day/month Day 1 Year 1 Year 2 Year 3 Year 4 Year 5
Visit window (days) ±21 ±21 ±21 ±21 ±21
Informed consent ×
Eligibility criteria × ×
Demography ×
Kidney biopsy ×
Medical history × × × × × × ×
Quality ofLife questionnaires × × × × × ×
Concomitant medication × × × × × × ×
Physical examination × × × × × × ×
Weight/height/body surface 
area
× × × × × × ×
Vital signs × × × × × × ×
Laboratory blood sample × × × × × × ×
Urine sample × × × × × × ×
ECG and ECHO × × ×
measured GFR × × ×
MRI‡ ×§ ×¶ × ×
Retinal screening
(OCT- A)
×** × × × × ×
*Where less than 5 years is available between recruitment and the end of the study the final study visits (month 60) may be brought forward.
†If patients have an additional kidney biopsy for a clinical cause we will perform an additional MRI within 8/52 of biopsy.
‡All MRI visits to be performed at the same time during the day (±2 hours).
§The first five patients recruited at each site will undergo an MRI scan to confirm that the MRI image acquisition is suitable and to optimise
the MRI methods that will be used subsequently. ECG and ECHO will be performed in accordance with local protocols and standards of
care. Routine haematology and biochemistry measurements will be conducted using the clinical laboratories at Barts Health and the Royal
Free London. (Fasting c- peptide (first visit only), fasting cholesterol, FBC, U&E, bone and LFT, 25OH vitamin D, bicarbonate, CRP, glucose,
haemoglobin A1c, plasma osmolarity, urine creatinine, protein, albumin, sodium, Potassium and urine culture. Day case kidney biopsy will be
performed as per routine clinical care. Clinical samples will be processed and reported using internationally accepted protocols.22 Patients
will be scanned on two different 1.5 T MR systems (Siemens Healthineers, Erlangen, Germany and GE Healthcare, Milwaukee, Wisconsin,
USA). MRI protocols will be similar across both MRI systems. A nuclear medicine (Cr- EDTA) measured GFR will be performed as per standard
clinical protocol in parallel to OCT- A and MRI scans. Whole blood, serum, plasma and urine samples will also be biobanked for future use.
¶Baseline MRI to be performed at the earliest 4 weeks, but not later than 12 weeks after kidney biopsy.
**Baseline retinal screening (with SS- OCT- A) will be performed as near to visit 1 as possible (±8/52). Additional yearly retinal screening will be 
performed using either standard retinal photography or SS- OCT- A to achieve a cost neutral retinal screening programme.
CRP, C reactive protein; DCCT, diabetes control and complications trial; ECHO, echocardiography; FBC, full blood count; LFT, liver function 
test; SS- OCT- A, swept- source optical coherence tomography angiography; U&E, urea and electrolytes.
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amyloidosis), then these patients will be excluded from 
the study.
MRI procedure
The baseline MRI scan will occur up to 12 weeks after a 
kidney biopsy. MRI assessment variables for kidney and 
cardiac function, morphology and arterial stiffness are 
outlined in online supplementary table 3. MRI data acqui-
sition will be prioritised in the following order: kidney, 
cardiac and arterial stiffness. The total scan time for the 
full imaging protocol is estimated to be approximately 
45 min. To minimise physiological variations, patients 
will be asked to drink at least 250 mL water within the 
hour immediately before the scan to better standardise 
hydration status. Patients will also be instructed to abstain 
from products containing nicotine, alcohol and caffeine 
for at least 6 hours prior to the scan. All static images will 
be subjected to a radiological assessment by qualified 
medical personnel at each MRI site for any incidental 
findings. Pseudonymised images will be sent to Antaros 
Medical (Sweden) for analysis of study endpoints using a 
dedicated software package and certified image analysts. 
MRI image analysis will be performed blinded to all 
personally identifiable information as well as clinical and 
histological makers.
Retinal imaging
Images will be obtained at similar time points to the MRI 
scans with the Triton OCT Platform (Topcon, Tokyo, 
Japan). SS- OCT- A is a non- invasive technique obtaining 
cross- sectional and en- face high resolution images of 
the retina and choroid. The higher wavelength allows 
in depth visualisation of all retinal and choroidal layers 
in high resolution.20 Patients will have non- invasive 
structural posterior pole OCT imaging collected at the 
same time as the SS- OCT- A. Patients will continue to 
undergo fundus photography annually as part of their 
standard of care diabetic retinopathy screening. OCT- A 
assessment variables are outlined in online supplemen-
tary table 3.
The SS- OCT- A and SS- OCT images will be acquired 
according to a standard protocol within 8 weeks of base-
line, at 1 year and 5 years. The thickness and features of 
the retinal and choroidal sublayers will be assessed on 
structural cross- sectional and en face OCT imaging.23 
OCT- A parameters that will be assessed include the foveal 
avascular zone area and circulation, intercapillary areas 
and vessel densities19 24 at the retinal vascular layers and 
the choriocapillaris layers (signal voids).20 Juxtaposi-
tion with fundus images will allow the colocalisation of 
findings.
Analysis
Primary and secondary outcome variables are outlined 
in online supplementary table 4. The primary outcome 
is time to the composite of death, renal replacement 
therapy or 30% decline in eGFR
Sample size
Five hundred patients will be recruited to HEROIC with 
10 additional healthy volunteers. This is an exploratory 
and hypothesis generating observational study and this 
sample size is based on pragmatic considerations. This, 
the number that could be feasibly recruited, and the 
investigations performed, given time constraints of the 
study along with local capacity.
However, to provide some context, we estimate we will 
have 90% power to detect associations between the histo-
logical scores22 and the primary endpoint. For example, 
assuming a binary histological parameter (eg, vascular 
score coded as high vs low, eg, a score of 2, ‘more than 
one area of arteriolar hyalinosis’, versus 0 or 1 ‘one or 
no areas’22), which 20% of the population experience, 
associated with an HR of 2.0 for the primary outcome 
(which we assume will occur in 40% of the total study 
population), the sample size of 500 would provide 92% 
power to detect an association at α=0.01. Furthermore, 
we also predict there will be substantial power to detect 
associations (eg, perfusion index coded as low vs high on 
kidney MRI parameters) with estimated or measured GFR 
decline over time. Details of these secondary analyses are 
presented in the supplementary materials.
Ethics and dissemination
Ethical approval has been obtained from the Blooms-
bury Research Ethics Committee (REC 18- LO-1921). 
Any patient identifiable data will be stored on a password 
protected National Health Service N3 network with full 
audit trail. Anonymised imaging data will be stored in a 
ISO27001 certificated data warehouse.
Patient and public involvement
Patients were not directly involved in the development of 
the study, design or implementation; however, all patient 
facing documents were presented to patients attending 
the Royal London Hospital for their feedback, and 
amendments were made accordingly. Patient and public 
engagement events and study result dissemination are 
planned during the study and following completion.
DISCUSSION
Clinically, DKD is characterised by progressive kidney damage 
reflected by increased albuminuria, impairment in kidney 
function (decline in eGFR), elevated blood pressure and 
excess morbidity and mortality due to cardiovascular compli-
cations. The classification of DKD based on albuminuria and 
eGFR level is simple, affordable, accessible in daily clinical 
practice, provides prognostic information and is helpful to 
guide therapeutic decisions but is not without shortcom-
ings. Not all patients with impaired kidney function (eGFR 
<60 mL/min per 1.73 m2) or significant albuminuria prog-
ress to ESKD or develop cardiovascular disease (reviewed 
in refs 25 26), and there remains a high degree of hetero-
geneity in the clinical presentation, histopathology, rate of 
progression and complications of disease. The clinical need 
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for more specific diagnostic and prognostic tools in early and 
late stages of DKD and improved biomarkers that can deter-
mine the aetiology of the kidney disease and characterise the 
dominant pathophysiological process in individual patients 
are required.
HEROIC is the first study of its kind to standardise inclu-
sion criteria by only including patients with biopsy proven 
DKD from a multiethnic population. This not only allows an 
affirmative diagnosis of DKD based on histological analysis of 
tissue samples22 27but will also help to characterise the range 
of pathological features of kidney disease in patients with 
diabetes28 29 and provides a basis for correlating histology with 
the clinical phenotype of DKD. The potential for renal biop-
sies to identify alternative renal pathologies will also serve to 
benefit patients enrolled in this study by potentially altering 
the clinical management of their kidney disease. However, 
renal biopsy has disadvantages: it is invasive (causing discom-
fort and risking complications), it is susceptible to sampling 
bias (only ~0.002% of the total glomeruli of one kidney) and 
it is difficult to perform repeatedly to assess serial changes.
MRI is emerging as a promising non- invasive imaging tool 
to address these challenges. Renal MRI may complement 
or even provide an alternative to kidney biopsies, with the 
advantage of separate evaluation of both kidneys in their 
entirety, avoiding the sampling bias associated with a kidney 
biopsy, as well as allowing for detection of regional variations. 
MRI also provides a variety of imaging parameters that can 
differentiate pathological from healthy tissues, according to 
biophysical changes that have been linked to hemodynamics, 
interstitial fibrosis, tissue inflammation, perfusion, filtration 
and tissue oxygenation.16 The association of kidney imaging 
parameters with histological measures of fibrosis, inflamma-
tion, peritubular capillary density and podocyte loss, as well 
as OCTA- A data, blood or urinary markers of kidney dysfunc-
tion, metabolic disturbance and inflammation will be a key 
aspect of HEROIC.
Central to HEROIC is the establishment of a bioresource 
through serial collection of biological samples, which will 
permit assessments of combinations of genetic, molecular 
and imaging biomarkers, and ultimately link clinical data 
with biosamples and MRI parameters. This approach may 
identify novel makers of kidney disease and its progression 
and uncover key mechanistic pathways underlying the patho-
genesis of DKD. Use of panels of urine and blood injury 
markers will also provide an additional means of establishing 
biological validity of MRI measures in DKD.
During the course of this study, patients will also be 
seen in a comprehensive DKD clinic providing them with 
access to high- quality clinical care, as well as potentially 
providing access to interventional research studies.
Limitations
Given the ‘deep’ phenotyping of study participants, the 
sample size is moderate, which may limit the power to detect 
associations in stratified analyses (eg, by ethnicity). In addi-
tion, although the inclusion criteria are broad by design, not 
all patients with DKD will be recruited, and the findings from 
HEROIC may not be generalisable to all those excluded on 
the basis of the initial biopsy or who are unwilling to undergo 
this procedure who may be at low- risk of progression. Specif-
ically those with low- level proteinuria and stable eGFR, who 
may not progress to ESRD but nonetheless at high risk of CV 
complications, will not be included.
Furthermore, although loss of kidney function is typically 
relatively rapid in those with DKD and moderate to heavy 
proteinuria, it is possible that eGFR decline rates are retarded 
by the high- intensity multidisciplinary care provided to partic-
ipants in HEROIC, thereby reducing the power to detect 
associations between MRI parameters and adverse kidney 
outcomes. Finally, although the retinal imaging approaches 
are ‘state of the art’, the peripheral retina cannot easily be 
visualised with current commercially available SS- OCT- A 
technology, meaning that informative findings from the 
peripheral retinal vasculature may be missed.
Summary paragraph
HEROIC is the first study multiethnic longitudinal study 
with standardised inclusion criteria of patients with biopsy 
proven DKD. This work will provide insight into the rela-
tionships between invasive and non- invasive assessment 
of kidney parameters and will characterise the cardiac 
and vascular associations of progressive DKD and also 
be a unique bioresource for the further investigation of 
broader aetiopathogenesis of DKD.
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